Perhaps I'll start, and I'll turn it over to Frank, Madam Chair.
First of all, there is clearly a difference between mass production of vaccine in production facilities versus the capacity to do trial lot vaccines for research purposes. So the example that you give is a very real one, and that's part of the reason why there is collaboration between different levels of government and GlaxoSmithKline in terms of production of a new fill line. But that's in terms of production during a pandemic or for seasonal purposes. In terms of the production of trial lots, it's very different in terms of size, scope, etc., and I'll let Frank speak to it, because we actually have very practical experience because we do experimental vaccines. We produce experimental vaccines and need vaccine manufacturers in terms of trial lot manufacturers—not big commercial enterprises per se—to be able to do that. Frank can actually speak to our practical experience as opposed to the theoretical.